Sanofi-Aventis agreed to pay $109 million to resolve allegations that the company gave doctors free units of Hyalgan (an injection to relieve knee pain) to encourage those doctors to buy their product. Sanofi lowered the effective price by promising these free samples to doctors, but at the same time got inflated prices from government programs by submitting false price reports, alleged the United States. Medicare and other government health care programs “paid millions of dollars in kickback-tainted claims for Hyalgan,” according to the DOJ announcement.
9
Endo
FEB 2014
Endo Health Solutions Inc. and its subsidiary Endo Pharmaceuticals Inc. agreed to pay $192.7 million to resolve criminal and civil liability arising from Endo’s marketing of the prescription drug Lidoderm. As part of the agreement, Endo admitted that it intended that Lidoderm be used for unapproved indications and that it promoted Lidoderm to healthcare providers this way.
8
AstraZeneca
APRIL 2010
AstraZeneca was fined $520 million to resolve allegations that it illegally promoted the antipsychotic drug Seroquel. The drug was approved for treating schizophrenia and later for bipolar mania, but the government alleged that AstraZeneca promoted Seroquel for a variety of unapproved uses, such as aggression, sleeplessness, anxiety, and depression. AstraZeneca denied the charges but agreed to pay the fine to end the investigation.
7
Amgen
DEC 2012
Amgen agreed to pay a $762 million fine to resolve criminal and civil charges that the company illegally introduced and promoted several drugs including Aranesp, a drug to treat anemia. Amgen pleaded guilty to illegally selling Aranesp to be used at doses that the FDA had explicitly rejected, and for an off-label treatment that had never been FDA-approved.
6
Merck
NOV 2011
Merck agreed to pay a fine of $950 million related to the illegal promotion of the painkiller Vioxx, which was withdrawn from the market in 2004 after studies found the drug increased the risk of heart attacks. The company pled guilty to having promoted Vioxx as a treatment for rheumatoid arthritis before it had been approved for that use. The settlement also resolved allegations that Merck made false or misleading statements about the drug’s heart safety to increase sales.
5
Eli Lilly
JAN 2009
Eli Lilly was fined $1.42 billion to resolve a government investigation into the off-label promotion of the antipsychotic Zyprexa. Zyprexa had been approved for the treatment of certain psychotic disorders, but Lilly admitted to promoting the drug in elderly populations to treat dementia. The government also alleged that Lilly targeted primary care physicians to promote Zyprexa for unapproved uses and “trained its sales force to disregard the law.”
4
Abbott
MAY 2012
Abbott was fined $1.5 billion in connection to the illegal promotion of the antipsychotic drug Depakote. Abbott admitted to having trained a special sales force to target nursing homes, marketing the drug for the control of aggression and agitation in elderly dementia patients. Depakote had never been approved for that purpose, and Abbott lacked evidence that the drug was safe or effective for those uses. The company also admitted to marketing Depakote to treat schizophrenia, even though no study had found it effective for that purpose.
3
Johnson & Johnson
NOV 2013
Johnson & Johnson agreed to pay a $2.2 billion fine to resolve criminal and civil allegations relating to the prescription drugs Risperdal, Invega and Natrecor. The government alleged that J&J promoted these drugs for uses not approved as safe and effective by the FDA, targeted elderly dementia patients in nursing homes, and paid kickbacks to physicians and to the nation’s largest long-term care pharmacy provider, Omnicare Inc. As part of the agreement, Johnson & Johnson admitted that it promoted Risperdal for treatment of psychotic symptoms in non-schizophrenic patients, although the drug was approved only to treat schizophrenia.
2
Pfizer
SEPT 2009
Pfizer was fined $2.3 billion, then the largest health care fraud settlement and the largest criminal fine ever imposed in the United States. Pfizer pled guilty to misbranding the painkiller Bextra with “the intent to defraud or mislead”, promoting the drug to treat acute pain at dosages the FDA had previously deemed dangerously high. Bextra was pulled from the market in 2005 due to safety concerns. The government alleged that Pfizer also promoted three other drugs illegally: the antipsychotic Geodon, an antibiotic Zyvox, and the antiepileptic drug Lyrica.
GlaxoSmithKline agreed to pay a fine of $3 billion to resolve civil and criminal liabilities regarding its promotion of drugs, as well as its failure to report safety data. This is the largest health care fraud settlement in the United States to date. The company pled guilty to misbranding the drug Paxil for treating depression in patients under 18, even though the drug had never been approved for that age group. GlaxoSmithKline also pled guilty to failing to disclose safety information about the diabetes drug Avandia to the FDA.
To be continued? Our work and existence, as media and people, is funded solely by our most generous supporters. But we’re not really covering our costs so far, and we’re in dire needs to upgrade our equipment, especially for video production. Help SILVIEW.media survive and grow, please donate here, anything helps. Thank you!
! Articles can always be subject of later editing as a way of perfecting them
Sometimes my memes are 3D. And you can own them. Or send them to someone. You can even eat some of them. CLICK HERE
Much like the Fed, CDC isn’t a government agency, it’s more like a prototype of today’s PPP’s (Private-Public Partnerships) used by the WEF to siphon public wealth into private pockets and subvert the political self-determination of the people.
One way for CDC to attract funds is their Foundation. And we can’t follow the money if we don’t even know who the sponsors are. If you had difficulties before in finding them, though I can’t imagine one, now you have no excuse, you just need to CLICK HERE to find out more about the conflict of interests in which Pharmafia thrives like a baby in the amniotic juice. Removing that womb would terminate this vile genocidal cartel. There’s more than just that page, but that’s where you start YOUR OWN RESEARCH.
Interestingly, the CDC Foundation self-portrait looks very much like Klaus Schwab:
“The CDC Foundation is an independent nonprofit and the sole entity created by Congress to mobilize philanthropic and private-sector resources to support the Centers for Disease Control and Prevention’s critical health protection work.
We are a catalyst for unleashing the power of collaboration between CDC and philanthropies, private entities and individuals to protect the health, safety and security of America and the world.
The government has unique capacities as well as limitations. The same is true for the private and philanthropic sectors. We believe that people, groups and organizations have greater positive impact and can accomplish more collectively than individually. By aligning diverse interests and resources and leveraging all parties’ strengths, our focused collaborations with private and philanthropic partners help create greater impact than any one entity can alone. Your support saves and improves lives—right now and in the future.
Thanks to our donors, we have launched approximately more than 1,200 health protection programs and raised over $1.2 billion to support CDC’s work over the past two decades. To keep people healthy, safe and secure, we managed hundreds of programs in the United States and in more than 140 countries.” – SOURCE
Now, to make my point, I just need to highlight some of the names found there, for your later references. These are some of the people who home-detain, muzzle and inject us. Interestingly, most of them are also partners in the World Economic Forum.
Before fusing humans with technology, the Schwaborg has fused Pharmafia with Big Tech, mainstream media and the Governments. These are not independent voices confirming one another, they’re the same entity, like the Borg (and I’ll prove later that Star Trek’s Borg is not just science-fiction entertainment).
If your nutritionist has a McDonalds badge, you have no nutritionist. Btw, many US and UK hospitals, maybe in other countries too, host McDonalds restaurants. Same people.
Some things are not meant to be businesses, public health is one of them.
To be continued? Our work and existence, as media and people, is funded solely by our most generous supporters. But we’re not really covering our costs so far, and we’re in dire needs to upgrade our equipment, especially for video production. Help SILVIEW.media survive and grow, please donate here, anything helps. Thank you!
! Articles can always be subject of later editing as a way of perfecting them
Imagine that the brutal experiments at Auschwitz were better concealed and the prisoners were drugged and brainwashed to believe that’s the best world out there for them. Then find out that the management has never stopped winning, expanding and perfecting their business model, up to today’s Great Reset.
Founded in Binghamton, New York, in 1901, Ansco was a manufacturer of photographic products and film. Ansco was originally founded through the merger of E. Anthony & Company and Scovill Manufacturing. In 1928, Ansco merged with Agfa to form Agfa-Ansco. The new corporation was a division of General Aniline and Film (GAF) Corporation, which was controlled by the German chemical cartel IG Farben. After Germany declared war on the United States in 1941, the United States Government seized the assets of GAF, including Agfa-Ansco. In 1943, the company removed “Agfa” from its name, once again becoming Ansco. The United States Justice Department oversaw Ansco’s operation until 1965, when government-held stock in GAF was sold to the public. In 1977, GAF eliminated its line of consumer photography products, including those manufactured by Ansco at the Binghamton facility. GAF also sold the Ansco trademark to Haking Enterprises. GAF continued to manufacture film at the Binghamton plant for industrial and medical use until 1981, when it sold the plant to Anitec Image Corporation. Over the next two decades, the former Ansco facility was sold several times, and in 2000, it was demolished.
Prior to the late 1970s, dozens of asbestos-containing materials were utilized in the construction and maintenance of buildings at Ansco’s Binghamton facility, including fireproof insulation, pipe covering and insulating cement. Inhaling dust from the application and removal of asbestos-containing materials placed workers at risk for developing an asbestos-related disease, such as mesothelioma or lung cancer.
Fireproof insulation was applied to structural steel during the construction of buildings at Ansco. Fireproofing materials were manufactured as a dry mixture of asbestos, linen and cement, packaged in fifty-pound paper bags. The dry mixture was mixed with water and sprayed onto the structural steel using a hose. Pouring, mixing and spraying fireproof insulation created clouds of asbestos-containing dust. After the fireproofing material was applied, it was typical for tradesmen, such as electricians or pipefitters, to scrape the fireproofing material from structural steel in order to install pipes and conduits. When the fireproof insulation was disturbed, asbestos fibers and dust became airborne.
Workers applied asbestos-containing pipe covering to pipes at the Binghamton Ansco facility. Pipe covering was applied to numerous piping systems in order to maintain stable internal temperatures and to protect pipes from damage. When pipe covering was applied, asbestos fibers were emitted. Insulating cement was also applied to pumps, valves and other equipment. It was manufactured as a powder and mixed with water to prepare it for application. Mixing insulating cement caused asbestos-containing dust to become airborne.
What’s Bayer been up to lately? We find out from their website:
The Bio Revolution is redefining innovation in the life sciences. How this might be a game changer.
The life sciences have made great advances in the past years. Biology, life sciences and the megatrend of digitization are growing closer together, enabling new inventions that impact our daily lives in a scope that we speak of a Bio Revolution. This revolution is reinforced by rapid increases in computing power and the emergence of new capabilities in AI, automation, and data analytics. These trends are further accelerating the pace of innovation and the potential for higher R&D productivity in the life sciences.
All this has led to new ways to understand and explore biology. The range of life forms on earth is incredibly complex and diverse. However, the methods to analyze them can be remarkably similar. Technologies and methods are transcending disciplinary boundaries even faster.
The implications across the life sciences can be enormous:
For human health, for example, a deeper understanding of the relationship between genetics and disease has led to the emergence of precision medicine, which can potentially be more effective than the one-size-fits-all therapies of the past. In the future, new technologies could help the healthcare industry not only treat, but cure or even prevent diseases. New gene and cell therapies, for example, aim to cure genetic diseases, potentially enabling sustainable organ replacement or reversing autoimmune diseases.
The Bio Revolution has the potential to help address some of the most critical global challenges, from climate change to pandemics, chronic diseases, and worldwide food security. Experts estimate that a significant portion of the economic impact of biological applications will be in health care, agriculture, and consumer products.3 Already today, the Bio Revolution with its convergence of science and technology has created an explosion of research projects in science and business. Each year, the amount of Intellectual Property related to the Bio Revolution is increasing.4 This can be seen, for example, by the number of patents in CrispR or plant biotech. In short: the revolution is gaining momentum and holds a great promise for health and food alike.
Total number of CRISPR patent applications worldwide per year from 1984 to 2018.
Fueled by digitalization, growing connectivity, and falling costs, important advances in biotechnology are intertwined with more systemic shift in how bio-innovation is undertaken and who is involved. Microbiome technologies, advanced genomics, gene editing and synthetic biology are among key enabling technologies that have the potential to change the face of bio-innovation. This broader redefinition of bio-innovation creates new prospects to help address important nutrition, environmental and development needs.
World Economic Forum, Bio-Innovation Dialogue Initiative
As a leading life science company, Bayer is aligned with the long-term market trends in health and nutrition and offers innovative and sustainable solutions to tackle some of the key challenges for humanity. Bayer brings to the table an extensive knowledge of human and plant science, supported by its expertise in regulatory processes and an impressive global footprint to ultimately bring innovations from labs to market. https://www.youtube-nocookie.com/embed/EYE1gya7XiM?autoplay=1&start=0&rel=0
The Bio Revolution marks the beginning of a new era: Innovations enabled by the convergence of biology and technology have the potential to significantly improve our lives, our nutrition, and our health.
Did you know that Bayer is at the forefront of the wave of innovation coming from the Bio Revolution?
The Bio Revolution is expected to transform healthcare and agriculture over the next decades – but the revolution is already happening now. With its newly established cell and gene therapy platform in Pharmaceuticals and innovative gene-editing tools such as CRISPR, Bayer operates at the core of the Bio Revolution and has tremendous opportunities to improve health and nutrition.
In Pharma, Bayer’s new Cell & Gene Therapy (CGT) platform steers our strategy in the area and orchestrates our activities along the value chain providing an innovation ecosystem for the companies – including BlueRock Therapeutics and Asklepios BioPharmaceutical (AskBio), which are fully owned by Bayer but operate autonomously. These therapies hold the potential to significantly impact patients’ lives by moving from treating symptoms to potentially curative approaches.
Bayer’s development portfolio of cell and gene therapies already comprises eight advanced assets in different stages of clinical development. These are applicable in multiple therapeutic areas with high unmet need, such as neurodegenerative, neuromuscular and cardiovascular indications, with programs in Pompe disease, Parkinson’s disease, hemophilia A, and congestive heart failure. With over 15 preclinical assets in the cell and gene therapy field, the pipeline is expected to grow steadily year by year.
Yet Bayer is not only using biotechnology to advance health – the promise for agriculture is just as inspiring. In the Crop Science Division, for example, tools like CRISPR can make changes to plant DNA with more precision than ever before and make plants more weather- or disease-resistant, enabling farmers to grow more or better-quality products under changing conditions.
Advancing genetic solutions for a sustainable future (1)PreviousNext
Did you know that Leaps by Bayer invests into potentially disruptive technologies to tackle some of the largest, unsolved challenges in the life sciences?
With Leaps by Bayer – our impact investment approach utilizing venture capital – we are constantly scanning for additional potential breakthroughs that hold promise to either cure or treat people from diseases or help feed a growing population with less impact on the environment.
$1 Billion
Since 2015, Leaps by Bayer has invested over $1 billion in ventures that tackle fundamental breakthroughs and shift core paradigms in our industries.
Leaps by Bayer has an investment focus on potentially disruptive solutions in the fields of healthcare and agriculture. The Leaps investment approach is remarkable: It aims to invest into or build up new innovative companies. Bayer supports those companies by enabling the exchange of proprietary assets, which can include sharing own patents or providing access to the Bayer network’s technical capabilities and 150 years of expertise. The companies remain autonomous with respect to decision making, while Leaps facilitates and supports them in a so-called active incubation process. Experienced team members actively engage in the young companies’ development by providing resources and helping them to steer the initial strategic direction. Today, the investment portfolio includes more than 35 companies advancing potential breakthrough technologies.
Leaps is our way of thinking big.
Werner Baumann, CEO of Bayer AG
Many Leaps ventures have made significant progress towards unlocking the potential of new technology platforms with a promising and transformative potential. BlueRock Therapeutics, for example, started as a Leaps investment and is now an integral part of Bayer’s CGT platform and just received clearance to proceed with a phase I trial in Parkinson’s disease.
Other companies, like the biopharmaceutical player Triumvira, are specialized on next generation immuno-oncology treatments. Triumvira focuses on novel T-cell therapies that aim to be safer and more efficacious than current cell therapy cancer treatments. Treating, curing and preventing cancer is one of the focus areas of Leaps by Bayer, since this group of diseases still represents one of today’s biggest health challenges with limited curative or preventative therapies available.
We face a huge disease burden, and the way we produce food isn’t sustainable for the planet. I believe the Bio Revolution can help us overcome these issues.
Jürgen Eckhardt, Head of Leaps by Bayer
Leaps is also investing in the development of sustainable biotechnological solutions in the field of agriculture. One of the ventures in this field is Joyn Bio, a company that aims to significantly reduce the environmental impact of synthetic nitrogen fertilizers through a technology that fixes nitrogen into the soil. Nitrogen is one of the most important nutrients essential for every plant to grow, however, its use and production as a fertilizer is estimated to contribute 3-5% to all global greenhouse gas emissions. Joyn Bio is working on an engineered microbe that enables cereal crops like corn, wheat, and rice to convert nitrogen from the air into a form they can use to grow. This technology may have the potential to help farmers use nitrogen in new ways, and as a result, reduce agriculture’s environmental footprint.
The Leaps by Bayer investment portfolio includes more than 35 companies.
At least that’s what Bayer says. All I know is that they’re still running the show.
To be continued? Our work and existence, as media and people, is funded solely by our most generous supporters. But we’re not really covering our costs so far, and we’re in dire needs to upgrade our equipment, especially for video production. Help SILVIEW.media survive and grow, please donate here, anything helps. Thank you!
! Articles can always be subject of later editing as a way of perfecting them
We gave up on our profit shares from masks, if you want to help us, please use the donation button! We think frequent mask use, even short term use can be bad for you, but if you have no way around them, at least send a message of consciousness. Get it here!
Fueled by digitalization, growing connectivity, and falling costs, important advances in biotechnology are intertwined with more systemic shift in how bio-innovation is undertaken and who is involved. Microbiome technologies, advanced genomics, gene editing and synthetic biology are among key enabling technologies that have the potential to change the face of bio-innovation. This broader redefinition of bio-innovation creates new prospects to help address important nutrition, environmental and development needs.
SILVIEW.media 